My highlight of the 2015 annual meeting of the American Society of Hematology (ASH) was interviewing Professor Waseem Qasim, who is a Consultant in Paediatric Immunology and Bone Marrow Transplantation at Great Ormond Street Hospital (GOSH) and Professor of Cell & Gene Therapy at the Institute of Child Health, which is part of University College London (UCL).
In a poster presented at ASH 2015, Prof Qasim together with colleagues from GOSH & UCL reported the “first in man” use of a gene edited, off-the-shelf, allogeneic CAR T cell from Cellectis, a company we have written extensively about on the blog. It was probably one of the leading posters at the meeting, at least in terms of the amount of interest it generated, and the crowds I saw reading it.
There was far too much content in the interview for one blog post, so we’ve split into two, with Part 1 focusing on gene editing and Part 2 discussing in detail the case reported in the poster.
Subscribers can login to read more or you can purchase access below.
Downtown Disney, Orlando
It’s an exciting week for cancer drug development with the AACR-NCI-EORTC molecular targets meeting in Boston (Twitter: #Targets15) and the 2015 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD (Twitter: #SITC2015)
However, today’s news is the much anticipated release of the abstracts (apart from the late breakers and press program) for the 2015 American Society of Hematology (ASH) annual meeting (Twitter: #ASH15) that takes place in Orlando from December 5-8th. We’ll at the meeting for the blog.
There is so much great science at ASH, it’s really hard to do it justice – we’ve been known to spend most of the meeting in the poster halls…and until you see the data it’s impossible to provide detailed commentary or analysis.
However, there’s so much interest in the abstracts that for the benefit of our subs, I’ve highlighted several that caught my attention in what is a fast, real-time, top-line review while at SITC this morning.
This initial review covers two hot topics in cancer immunotherapy – CAR T cells and Checkpoint inhibitors.
Subscribers can login below or you can purchase access if you’d like to read our SITC and ASH conference coverage.